<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551056</url>
  </required_header>
  <id_info>
    <org_study_id>11-100-0012</org_study_id>
    <nct_id>NCT01551056</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aciex Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aciex Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24%
      compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in
      the conjunctival allergen challenge (CAC) model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinorrhea at Duration of Action (16 Hours +1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinorrhea at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Pruritis at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritis at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Congestion at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Congestion at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Duration of Action (16 Hours + 1 Hour Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Study Medication at Visit 3A</measure>
    <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
    <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>AC-170 0.24%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-170 0%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0.24%</intervention_name>
    <description>1 drop in each eye at 2 separate times during a 14 day period</description>
    <arm_group_label>AC-170 0.24%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-170 0%</intervention_name>
    <description>1 drop in each eye at 2 separate times during a 14 day period</description>
    <arm_group_label>AC-170 0%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  positive bilateral conjunctival allergen challenge (CAC) reaction

        Exclusion Criteria:

          -  known contraindications or sensitivities to the study medication or its components

          -  any ocular condition that, in the opinion of the investigator, could affect the
             subjects safety or trial parameters

          -  use of disallowed medication during the period indicated prior to the enrollment or
             during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Greiner, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles River Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail Torkildsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey Ackerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ora, Inc.</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>June 27, 2017</results_first_submitted>
  <results_first_submitted_qc>September 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2017</results_first_posted>
  <disposition_first_submitted>April 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 19, 2015</disposition_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from three sites in the US.</recruitment_details>
      <pre_assignment_details>There were 91 subjects enrolled, 2 subjects discontinued, and 89 subjects completed the study. Participant flow and baseline characteristics are presented for the 91 subjects that met all inclusion criteria and none of the exclusion criteria and were randomized to receive AC-170 0.24% or AC-170 0%.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AC-170 0.24%</title>
          <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
        </group>
        <group group_id="P2">
          <title>AC-170 0%</title>
          <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AC-170 0.24%</title>
          <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
        </group>
        <group group_id="B2">
          <title>AC-170 0%</title>
          <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="14.95"/>
                    <measurement group_id="B2" value="38.1" spread="14.08"/>
                    <measurement group_id="B3" value="37.4" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.886"/>
                    <measurement group_id="O2" value="2.34" spread="0.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.910"/>
                    <measurement group_id="O2" value="2.50" spread="0.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.944"/>
                    <measurement group_id="O2" value="2.22" spread="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.638"/>
                    <measurement group_id="O2" value="2.18" spread="0.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.691"/>
                    <measurement group_id="O2" value="2.31" spread="0.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.783"/>
                    <measurement group_id="O2" value="2.10" spread="0.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.771"/>
                    <measurement group_id="O2" value="1.94" spread="0.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.777"/>
                    <measurement group_id="O2" value="2.02" spread="0.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.780"/>
                    <measurement group_id="O2" value="1.98" spread="0.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.728"/>
                    <measurement group_id="O2" value="2.05" spread="0.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.667"/>
                    <measurement group_id="O2" value="2.13" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.644"/>
                    <measurement group_id="O2" value="2.18" spread="0.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.786"/>
                    <measurement group_id="O2" value="1.82" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.825"/>
                    <measurement group_id="O2" value="1.96" spread="0.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.821"/>
                    <measurement group_id="O2" value="1.93" spread="0.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.810"/>
                    <measurement group_id="O2" value="1.90" spread="0.645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.789"/>
                    <measurement group_id="O2" value="1.99" spread="0.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.806"/>
                    <measurement group_id="O2" value="2.06" spread="0.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.719"/>
                    <measurement group_id="O2" value="1.94" spread="0.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.781"/>
                    <measurement group_id="O2" value="2.07" spread="0.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.768"/>
                    <measurement group_id="O2" value="2.03" spread="0.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.804"/>
                    <measurement group_id="O2" value="1.96" spread="0.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="0.791"/>
                    <measurement group_id="O2" value="2.10" spread="0.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="0.758"/>
                    <measurement group_id="O2" value="2.16" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.461"/>
                    <measurement group_id="O2" value="0.70" spread="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.605"/>
                    <measurement group_id="O2" value="1.01" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.605"/>
                    <measurement group_id="O2" value="1.05" spread="0.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.501"/>
                    <measurement group_id="O2" value="0.97" spread="0.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.685"/>
                    <measurement group_id="O2" value="1.42" spread="0.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.736"/>
                    <measurement group_id="O2" value="1.53" spread="0.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eyelid Swelling at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Eyelid Swelling at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.73"/>
                    <measurement group_id="O2" value="1.1" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.89"/>
                    <measurement group_id="O2" value="1.3" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.97"/>
                    <measurement group_id="O2" value="1.2" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eyelid Swelling at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Eyelid Swelling at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.65"/>
                    <measurement group_id="O2" value="0.9" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.74"/>
                    <measurement group_id="O2" value="1.1" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.79"/>
                    <measurement group_id="O2" value="1.1" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tearing at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Tearing at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.69"/>
                    <measurement group_id="O2" value="1.1" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.89"/>
                    <measurement group_id="O2" value="1.2" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.98"/>
                    <measurement group_id="O2" value="1.1" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tearing at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Tearing at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.57"/>
                    <measurement group_id="O2" value="1.0" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.87"/>
                    <measurement group_id="O2" value="0.8" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.88"/>
                    <measurement group_id="O2" value="0.8" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinorrhea at Duration of Action (16 Hours +1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinorrhea at Duration of Action (16 Hours +1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.89"/>
                    <measurement group_id="O2" value="1.4" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.03"/>
                    <measurement group_id="O2" value="1.3" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.10"/>
                    <measurement group_id="O2" value="1.4" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinorrhea at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinorrhea at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.64"/>
                    <measurement group_id="O2" value="1.1" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.73"/>
                    <measurement group_id="O2" value="1.0" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.82"/>
                    <measurement group_id="O2" value="1.0" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.72"/>
                    <measurement group_id="O2" value="1.0" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.03"/>
                    <measurement group_id="O2" value="1.0" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.95"/>
                    <measurement group_id="O2" value="1.1" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Pruritis at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Pruritis at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.53"/>
                    <measurement group_id="O2" value="0.7" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.59"/>
                    <measurement group_id="O2" value="0.8" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.73"/>
                    <measurement group_id="O2" value="0.7" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.69"/>
                    <measurement group_id="O2" value="1.0" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.13"/>
                    <measurement group_id="O2" value="1.3" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.16"/>
                    <measurement group_id="O2" value="1.5" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritis at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritis at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.51"/>
                    <measurement group_id="O2" value="1.0" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.66"/>
                    <measurement group_id="O2" value="1.1" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.69"/>
                    <measurement group_id="O2" value="1.0" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Congestion at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Congestion at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.94"/>
                    <measurement group_id="O2" value="1.3" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.04"/>
                    <measurement group_id="O2" value="1.5" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.15"/>
                    <measurement group_id="O2" value="1.4" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Congestion at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Congestion at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.60"/>
                    <measurement group_id="O2" value="1.0" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.86"/>
                    <measurement group_id="O2" value="1.2" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.10"/>
                    <measurement group_id="O2" value="1.2" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Duration of Action (16 Hours + 1 Hour Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>%participants with at least 1 nasal symp</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) with observed data only.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.</description>
          <population>Intent to Treat (ITT) with observed data only.</population>
          <units>%participants with at least 1 nasal symp</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9"/>
                    <measurement group_id="O2" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Study Medication at Visit 3A</title>
        <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
        <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-170 0.24%</title>
            <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
          <group group_id="O2">
            <title>AC-170 0%</title>
            <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Study Medication at Visit 3A</title>
          <description>Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upon instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.44"/>
                    <measurement group_id="O2" value="0.9" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.37"/>
                    <measurement group_id="O2" value="0.6" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minutes post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.29"/>
                    <measurement group_id="O2" value="0.6" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through the duration of the study, over the course of approximately 3 months. All subjects who received study medication were evaluable for the safety analysis.</time_frame>
      <desc>Throughout the visits, staff collected all Adverse Events reported, elicited or observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>AC-170 0.24%</title>
          <description>AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period</description>
        </group>
        <group group_id="E2">
          <title>AC-170 0%</title>
          <description>AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael V.W. Bergamini, PhD - Chief Scientific Officer/Executive Vice President</name_or_title>
      <organization>Nicox Ophthalmics Inc.</organization>
      <phone>817-529-9315</phone>
      <email>bergamini@nicox.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

